DEM BioPharma

Executive Summary

DEM BioPharma is a private biotechnology company founded in 2020, headquartered in San Diego with a Cambridge, MA office, focused on developing first-in-class macrophage engager therapies for solid tumors. The company's platform leverages the innate immune system, specifically macrophages, to target and eliminate cancer cells, addressing a key limitation in current immunotherapies that rely primarily on T-cell activation. While still in early stages with limited public information, DEM BioPharma has assembled a leadership team with expertise in innate immunity and biologics. The company is likely advancing its lead candidate toward IND-enabling studies. The macrophage engager space is gaining traction, with potential for differentiated efficacy in cold tumors, but the field remains nascent and competitive. Given the early stage and lack of disclosed data, the near-term risk is high, but the platform's novelty offers significant upside if successful.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Macrophage Engager Candidate50% success
• Q3 2026Presentation of Preclinical Proof-of-Concept Data at Scientific Conference65% success
• Q4 2026Series A Financing or Strategic Partnership Announcement40% success